ArticleThe Journal of experimental medicine2013
Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes.
Article in The Journal of experimental medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Clinical parameters and emerging biomarkers of partial remission in pediatric type 1 diabetes: a systematic review.Frontiers in endocrinology · 2026Pooled it
- A proteomic meta-analysis refinement of plasma extracellular vesicles.Scientific data · 2023Pooled it
- Complement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY Study.Scientific reports · 2016Trial
- Genetic mapping of complement system proteins for islet autoimmunity in children with high risk of T1D.Communications biology · 2025Article
- Binary classification of gynecological cancers based on ATR-FTIR spectroscopy and machine learning using urine samples.Clinical and experimental medicine · 2025Article
- Tear Proteomics in Children and Adolescents with Type 1 Diabetes: A Promising Approach to Biomarker Identification of Diabetes Pathogenesis and Complications.International journal of molecular sciences · 2024Article
- Plasma proteomics in children with new-onset type 1 diabetes identifies new potential biomarkers of partial remission.Scientific reports · 2024Article
- Multi-omics analysis of diabetic pig lungs reveals molecular derangements underlying pulmonary complications of diabetes mellitus.Disease models & mechanisms · 2024Article
- Decrease in multiple complement proteins associated with development of islet autoimmunity and type 1 diabetes.iScience · 2024Article
- Genetic variants in the complement system and their potential link in the aetiology of type 1 diabetes.Diabetes/metabolism research and reviews · 2024Review
- Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory.Diabetologia · 2023Article
- B-1 B Cell-Derived Natural Antibodies against N-Acetyl-d-Glucosamine Suppress Autoimmune Diabetes Pathogenesis.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Proteomic analysis of neonatal mouse hearts shows PKA functions as a cardiomyocyte replication regulator.Proteome science · 2023Article
- Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes.Scientific reports · 2023Article
- Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism, and immune response.Clinical proteomics · 2023Review
- Plasma protein biomarkers trailblaze as early predictors of type 1 diabetes.Cell reports. Medicine · 2023Article
- Plasma protein biomarkers predict the development of persistent autoantibodies and type 1 diabetes 6 months prior to the onset of autoimmunity.Cell reports. Medicine · 2023Article
- Plasma gelsolin levels are associated with diabetes, sex, race, and poverty.Journal of translational medicine · 2023Article
- Pathological mechanisms of type 1 diabetes in children: investigation of the exosomal protein expression profile.Frontiers in endocrinology · 2023Article
- Circulating platelet-neutrophil aggregates characterize the development of type 1 diabetes in humans and NOD mice.JCI insight · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Using global liquid chromatography-mass spectrometry (LC-MS)-based proteomics analyses, we identified 24 serum proteins that were significantly variant between those with type 1 diabetes (T1D) and healthy controls. Functionally, these proteins represent innate immune responses, the activation cascade of complement, inflammatory responses, and blood coagulation. Targeted verification analyses were performed on 52 surrogate peptides representing these proteins, with serum samples from an antibody standardization program cohort of 100 healthy control and 50 type 1 diabetic subjects. 16 peptides were verified as having very good discriminating power, with areas under the receiver operating characteristic curve ≥ 0.8. Further validation with blinded serum samples from an independent cohort (10 healthy control and 10 type 1 diabetics) demonstrated that peptides from platelet basic protein and C1 inhibitor achieved both 100% sensitivity and 100% specificity for classification of samples. The disease specificity of these proteins was assessed using sera from 50 age-matched type 2 diabetic individuals, and a subset of proteins, C1 inhibitor in particular, were exceptionally good discriminators between these two forms of diabetes. The panel of biomarkers distinguishing those with T1D from healthy controls and those with type 2 diabetes suggests that dysregulated innate immune responses may be associated with the development of this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.